• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To register, simply click the Register button at the top right.

New site I find helpful... CFS MCS Fibro crossover ect...

btdt

Senior Member
Messages
161
Location
Ontario
This is a new to me site I find very helpful tho they are far away they appear to be ahead on many issues... you can find them here.
http://www.asehaqld.org.au/index.ph...ns-of-psychosomatic-labelling-of-mcs-patients


There is a lot of crossover...be it incorrect dx or whatever we all know the stigma that comes from all these illnesses this article looks further issues caused by the lack of respect and lack of belief... no matter what one you have mcs fibro cfs crossover... bet this hits home for you.
Social and Medical Implications of Psychosomatic labelling MCS
Comparative investigations in referral clinic populations have reported that up to

  • 70% of patients with fibromyalgia meet the case definition for the chronic fatigue syndrome and, conversely, that
  • 35% to 70% of patients with the chronic fatigue syndrome have fibromyalgia.
  • Moreover, 13% to 18% of patients with temporomandibular disorder meet fibromyalgia criteria and
  • 75% of patients with fibromyalgia satisfy the case definition for temporomandibular disorder.
  • Other painful conditions, such as tension headache, also commonly co-occur with fibromyalgia.
  • Furthermore, 32% to 80% of patients with fibromyalgia, 58% to 92% of patients with the chronic fatigue syndrome, and 64% of patients with temporomandibular disorder also have IBS.
  • Conversely, 32% to 65% of those with IBS meet the criteria for fibromyalgia.
  • Moreover, one study showed that the symptoms reported by patients with fibromyalgia and patients with interstitial cystitis were more similar to each other than to those reported by healthy controls.
  • Finally, in 53% to 67% of persons with the chronic fatigue syndrome, illness worsens with exposure to various chemicals, and
  • 55% of persons with fibromyalgia have symptoms consistent with multiple chemical sensitivity.
  • In contrast, 30% of patients with multiple chemical sensitivity meet the criteria for the chronic fatigue syndrome.
Taken together, these direct comparisons of patient groups generally demonstrate high rates of diverse clinical conditions regardless of the condition examined.”

“In studies that assessed patients with a single unexplained clinical condition for the presence of at least one additional syndrome found that,

  • among patients with fibromyalgia,
    • 21% to 80% have coexisting chronic fatigue syndrome (39, 43, 61),
    • 36% to 60% have IBS (8, 27, 32, 40, 43, 48, 51),
    • 10% to 80% have headaches (27, 32, 43, 57),
    • 75% have mandibular dysfunction (35), and
    • 33% have multiple chemical sensitivity (54).
    • Many patients with the chronic fatigue syndrome also have
      • IBS (63%) (49),
      • multiple chemical sensitivity (41%) (64), and
      • other unexplained illnesses (67).
      • Of interest, these studies suggest that sex may influence the co-occurrence of unexplained clinical conditions. For example,
        • IBS is more common among women (40%) than men (14%) with fibromyalgia (66), and
        • fibromyalgia occurs more often in women (36%) than men (12%) with the chronic fatigue syndrome (12).”
“The patients’ symptoms and syndromes have been called “functional,” “somatic,” “medically unexplained,” and “psychosomatic....A major limitation of all categories of explanatory models is their inability to account for the occurrence of unexplained clinical conditions in a large proportion of affected patients (for example, many patients do not have depression, have not been abused, or do not demonstrate neuroendocrine changes at the time of testing).” (Aaron and Buchwald, 2001)